Interim guidelines: "Diseases of the digestive organs in the context of a new coronavirus infection pandemic (COVID-19)"

Драпкина, О. М.; Mayev, I. V.; Бакулин, И. Г.; Никонов, Е. Л.; Chulanov, Vladimir; Белоусова, Е. А.; Веселов, А. В.; Сайганов, С А; Симаненков, В. И.; Bakulin, N. V.; Avalueva, E. B.; Oganezova, I.A.; Skalinskaya, M. I.; Skazayeva, E. V.; Kashin, Sergey; Kuvaev, R. O.

doi:10.17116/profmed202023032120

Cited by 24 publications

(7 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…В качестве дополнения допускается использование блюд оптимизированного состава для основных вариантов стандартных диет, применяемых в лечебной питании в медицинских организациях РФ, включая отварные или запечённые блюда из мяса, птицы, рыбы, творога, яиц, овощей, кисломолочные продукты [368]. Лечебное питание осуществляется в стационаре и в течение не менее 2 недель после выписки.…”

Section: лечебное питаниеunclassified

Gastrointestinal disorders in post-COVID syndrome. Clinical guidelines

Гриневич

Лазебник

Kravchuk

et al. 2023

jour

View full text Add to dashboard Cite

Summary Post- COVID syndrome refers to the long-term consequences of a new coronavirus infection COVID-19, which includes a set of symptoms that develop or persist after COVID-19. Symptoms of gastrointestinal disorders in post- COVID syndrome, due to chronic infl ammation, the consequences of organ damage, prolonged hospitalization, social isolation, and other causes, can be persistent and require a multidisciplinary approach. The presented clinical practice guidelines consider the main preventive and therapeutic and diagnostic approaches to the management of patients with gastroenterological manifestations of postCOVID syndrome. The Guidelines were approved by the 17th National Congress of Internal Medicine and the 25th Congress of Gastroenterological Scientifi c Society of Russia.

show abstract

Section: лечебное питаниеunclassified

Gastrointestinal disorders in post-COVID syndrome. Clinical guidelines

Гриневич

Лазебник

Kravchuk

et al. 2023

jour

View full text Add to dashboard Cite

show abstract

“…В настоящее время описаны следующие изменения поджелудочной железы при COVID-19: преходящий стеатоз, отек поджелудочной железы без значимого некроза поджелудочной железы, сочетающийся с выраженным дуоденитом, проявления истинной внешнесекреторной недостаточности поджелудочной железы, требующие коррекции [283,284]. При тяжелом течении инфекции COVID-19 у 16% пациентов выявляются увеличение активности амилазы и липазы в сыворотке крови, а у 7% определяются выраженные изменения ткани поджелудочной железы при КТ брюшной полости [285].…”

Section: клиническая картинаunclassified

“…При выявлении обострения хронического панкреатита, прежде всего, необходимо уточнить степень его тяжести (исключение острого панкреатита), для чего определяют и динамически наблюдают за клинической симптоматикой (кожные проявления -гиперемия, «мраморность», цианоз; проявления энцефалопатии, гипотония -систолическое АД менее 100 мм рт. ст., снижение диуреза), лабораторными показателями -содержание лейкоцитов (ОАК), глюкозы, мочевины, кальция, КЩР [285,291], проводят уточняющие инструментальные исследо-вания МРТ, КТ ОБП (ЭндоУЗИ). При установлении признаков острого панкреатита -продолжение лечения в условиях хирургического стационара.…”

Section: диагностикаunclassified

Management of patients with digestive diseases during the COVID-19 pandemic. Clinical Practice Guidelines by the Russian scientiﬁc medical society of internal medicine (RSMSIM) and the Gastroenterological Scientiﬁc Society of Russia (2nd edition)

Гриневич

Kravchuk

Педь

et al. 2021

jour

View full text Add to dashboard Cite

The presented clinical practice guidelines of the Gastroenterological Scientiﬁc Society of Russia (GSSR), diagnostic, and therapeutic approaches for patients with digestive diseases during the COVID-19 pandemic. The guidelines were approved by the XXIII Congress of the GSSR and the 22nd International Slavonic-Baltic Scientiﬁ c Forum “St. Petersburg - Gastro-2020 ON-LINE” (St. Petersburg, June 11, 2020). The presented clinical practice guidelines of the Russian Scientiﬁc Medical Society of Internal Medicine (RSMSIM) and the Gastroenterological Scientiﬁc Society of Russia (GSSR), diagnostic, and therapeutic approaches for patients with digestive diseases during the COVID-19 pandemic. The recommendations were approved at the XV National Congress of Internal Medicine, XXIII Congress of NOGR on the basis of the 1st edition, adopted at the 22nd International Slavic- Baltic Scientiﬁc Forum “St. Petersburg - Gastro-2020 ON-LINE”.

show abstract

“…Ще однією особливістю ведення пацієнтів із НПЗП-індукованими ураженнями шлунково-кишкового тракту в умовах пандемії COVID-19 є максимальне використання амбулаторно-поліклінічного етапу й дистанційних засобів комунікації. Усі додаткові лабораторно-інструментальні дослідження (у тому числі рН-метрія, рН-імпедансометрія, манометрія стравоходу, діагностика H.pylori) у пацієнтів з низьким ризиком розвитку ускладнень і онкопатології, як правило, відкладаються на постпандемічний період [22].…”

Section: рисунок 1 -анкета для реконвалесцентів після Covid-19unclassified

Gastrointestinal disorders in patients with COVID-19: diagnoses and treatment during the pandemic

Paliy

Заика

Chernova

et al. 2021

GASTRO

View full text Add to dashboard Cite

Background. The pandemic caused by the coronavirus disease 2019 (COVID-19) is a topic that is currently in the spotlight of the world community. The use of non-steroidal anti-inflammatory drugs (NSAIDs) in combination with new oral anticoagulants (dabigatran, rivaroxaban, apixaban, etc.) and acetylsalicylic acid by the significant number of patients during the pandemic, caused by COVID-19, raises the question about the safety of the influence of each drug on the occurrence of gastrointestinal complications. The development of algorithms to prevent damage to the gastrointestinal mucosa on the background of these drugs is becoming a priority. The purpose was to examine the presence of gastrointestinal disorders using the Gastrointestinal Symptom Rating Scale (GSRS) in convalescents after COVID-19 and to evaluate the effectiveness of esomeprazole for correction of these disorders. Materials and methods. We surveyed 92 (48 men and 44 women) convalescents after COVID-19. The mean age of individuals was (49.2 ± 2.0) years. To conduct a survey of patients who had COVID-19, we developed a questionnaire which included patient’s passport data, age, gender. In addition, patients reported how COVID-19 was diagnosed, what drugs they were taking during treatment, and whether they needed oxygen therapy. Subsequently, convalescents after COVID-19 answered questions from the GSRS. Information was collected and the questionnaire was completed by telephone survey. Depending on the data of GSRS, esomeprazole (Ezonexa) was prescribed to patients at a dose of 20 mg 1 time per day, 30 minutes before meals, for 30 days. During the follow-up survey on day 30 of esomeprazole intake, patients re-answered the GSRS questions. Results. Thirty days after starting esomeprazole intake at a dose of 20 mg 1 time per day, 92 convalescents after COVID-19 showed a significant reduction (p < 0.001) in the manifestations of reflux, abdominal pain and dyspeptic syndromes compared to the results before treatment ((2.3 ± 0.1), (4.3 ± 0.2), (5.7 ± 0.3) versus (4.3 ± 0.3), (9.3 ± 0.4), (8.6 ± 0.6), respectively). Esomeprazole was equally effective (p > 0.05) in influencing the severity of reflux, abdominal pain, dyspeptic, diarrheal and constipation syndromes in both men and women: (2.3 ± 0.1), (4.3 ± 0.2), (5.7 ± 0.3), (3.9 ± 0.3), (3.0 ± 0.1) versus (2.4 ± 0.1), (4.2 ± 0.2), (6.0 ± 0.4), (4.0 ± 0.4), (3.1 ± 0.1), respectively. Esomeprazole was also equally effective (p > 0.05) in the impact on the severity of reflux, abdominal pain, dyspeptic, diarrheal and constipation syndromes among patients receiving acetylsalicylic acid and those treated with rivaroxaban: (2.5 ± 0.2), (4.2 ± 0.2), (5.6 ± 0.2), (3.9 ± 0.4), (3.1 ± 0.1) versus (2.2 ± 0.1), (4.4 ± 0.3), (6.4 ± 0.6), (4.2 ± 0.4), (3.0 ± 0.1), respectively. Esomeprazole at a dose of 20 mg 1 time per day was equally effective (p > 0.05) in relation to the dynamics of the severity of syndromes in patients receiving paracetamol and one NSAID and in those receiving paracetamol and 2 NSAIDs. In particular, in people receiving paracetamol and one NSAID, on the background of esomeprazole administration, the severity of reflux, abdominal pain, dyspeptic, diarrheal and constipation syndromes were (2.4 ± 0.1), (4.3 ± 0.2), (5.8 ± 0.3), (4.1 ± 0.3), (3.1 ± 0.1) and in patients taking paracetamol and 2 NSAIDs — (2.1 ± 0.2), (4.5 ± 0.4), (6.7 ± 0.7), (4.4 ± 0.7), (3.0 ± 0.1), respectively. Conclusions. Esomeprazole (Ezonexa) effectively reduces (p < 0.001) the severity of reflux, abdominal pain and dyspeptic syndromes in convalescents after COVID-19. The use of Esomeprazole (Ezonexa) demonstrates the same efficacy (p > 0.05) in men and women when receiving both ASA and rivaroxaban and during the treatment with both paracetamol and one NSAID and paracetamol and 2 NSAIDs.

show abstract

Interim guidelines: "Diseases of the digestive organs in the context of a new coronavirus infection pandemic (COVID-19)"

Cited by 24 publications

References 9 publications

Gastrointestinal disorders in post-COVID syndrome. Clinical guidelines

Gastrointestinal disorders in post-COVID syndrome. Clinical guidelines

Management of patients with digestive diseases during the COVID-19 pandemic. Clinical Practice Guidelines by the Russian scientiﬁc medical society of internal medicine (RSMSIM) and the Gastroenterological Scientiﬁc Society of Russia (2nd edition)

Gastrointestinal disorders in patients with COVID-19: diagnoses and treatment during the pandemic

Contact Info

Product

Resources

About